

Nixon & Vanderhye PC.

ATTORNEYS AT LAW

8TH FLOOR
1100 NORTH GLEBE ROAD
ARLINGTON, VIRGINIA 22201-4714TELEPHONE: (703) 816-4000
FACSIMILE: (703) 816-4100**FACSIMILE COVER SHEET****PLEASE DELIVER IMMEDIATELY!!!!***Copy*

Our Ref: 117 - 231
Your Ref: SN 08/776,350 Date: June 5, 1997
TO: Susan Unger
FIRM: US PTO
FACSIMILE NO.: 308-4242
FROM: Art Crawford
NUMBER OF PAGES (INCLUDING COVER SHEET): 5

(IF YOU DO NOT RECEIVE ALL OF THE PAGES OR ENCOUNTER DIFFICULTIES IN TRANSMISSION, PLEASE CONTACT US IMMEDIATELY AT (703-816-4000).)

FACSIMILE OPERATOR

ATTACHMENT/S: **Copy - Preliminary Amendment**
MESSAGE: **As requested this morning.**

OFFICIAL

FAX CENTER
RECEIVED
JUN 05 1997
GROUP 1800

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by

0089516.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MACLEAN et al
(National Phase PCT/GB95/01791)

Atty. Ref.: 117-231

Serial No. (To Be Assigned)

Group:

Filed: 28 January 1997

Examiner:

For: TREATMENT OF CANCER USING HSV MUTANT

January 28, 1997

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

FAX CENTER
RECEIVED

JUN 05 1997

GROUP 1800

PRELIMINARY AMENDMENT

Sir:

In order to place the above-identified application in better condition for examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please delete Claims 1 through 19 without prejudice.

PLEASE ADD THE FOLLOWING NEW CLAIMS -- 20 THROUGH 42 --

-- 20. A method of treating a secondary metastatic tumor in the central nervous system of a mammal, which method comprises the step of administering to the said mammal an effective amount of a mutant herpes simplex virus type 1 which has a non-functional γ 34.5 gene in the long repeat region (R_L).